Androgel Testosterone Gel

AndroGel is a widely prescribed topical testosterone replacement therapy developed to treat male hypogonadism. Originally created as a breakthrough in transdermal drug delivery, the product allows for a steady release of testosterone through the skin.

The brand has a complex corporate history. It was first introduced by Solvay Pharmaceuticals and Unimed Pharmaceuticals. Following a series of pharmaceutical acquisitions, the brand became part of Abbott Laboratories and was later spun off into AbbVie. It is now part of the Besins Healthcare portfolio in many international markets, while AbbVie continues to hold significant rights in others. Manufacturing is carried out in specialized pharmaceutical facilities across Europe and North America to meet global medical standards.